Neurodegenerative disease companies develop therapeutics, diagnostics and research technologies for conditions involving the progressive loss of neurons and nervous system function. Their work aims to improve disease detection, slow progression and address the underlying biology of neurodegeneration.
This category includes companies working on:
Browse 109 UK neurodegenerative disease companies below.
AI-enabled small molecule drug discovery
PharmEnable is a Cambridge-based drug discovery company developing novel small molecule therapeutics for targets that are inaccessible to biologics, including intracellular targets and those behind the blood-brain barrier. Its proprietary platform integrates AI and advanced medicinal chemistry to explore undercharted…
AI-driven natural product discovery for neurological therapeutics
Pangea Bio is a clinical-stage biotechnology company developing small molecule therapeutics for neurological and neuropsychiatric disorders. Its proprietary AI platform screens natural and plant-derived chemical space, integrating ethnobotanical data with machine learning to identify novel CNS drug candidates with…
High-affinity sheep monoclonal antibodies for clinical diagnostic testing
Bioventix is a UK biotechnology company that creates, manufactures and supplies high-affinity sheep monoclonal antibodies for clinical diagnostic applications, particularly where conventional antibodies have failed to detect low-concentration or difficult targets. Its antibodies are supplied to major multinational in…
Ion channel drug discovery platform for rare CNS disorders
Autifony Therapeutics is a clinical-stage UK biotech developing small molecule modulators of Kv3 voltage-gated potassium channels for rare genetic CNS disorders. Lead programmes target Fragile X syndrome and rare myoclonic epilepsy syndromes, with preclinical work extending to schizophrenia, hearing loss, and…
Transcription factor-targeting drug discovery for neurodegeneration
Scripta Therapeutics is an Oxford-based biotech company developing disease-modifying therapeutics by mapping and modulating transcription factor networks. Its platform integrates AI, imaging, and patient-derived models in a lab-in-the-loop workflow to identify compounds that restore healthy cellular states. The…
National institute researching dementia and neurodegenerative disease across the UK
The UK Dementia Research Institute is the UK's leading national institute dedicated to transforming outcomes for people affected by dementia and neurodegenerative conditions. Its central Hub at University College London coordinates seven research Centres hosted across leading UK universities, working towards new…
Antibody immunotherapy targeting toxic tau for neurodegenerative disease
TauC3 Biologics is a preclinical biopharmaceutical company developing an antibody-based immunotherapy that targets tauC3, a toxic, truncated form of the tau protein implicated in neurodegenerative disease. Its lead candidate, TBL-100, is a humanized monoclonal antibody developed with LifeArc, designed to selectively…
Therapeutics and blood biomarker tests for ALS
Vesalic develops therapeutic and diagnostic approaches for amyotrophic lateral sclerosis (ALS), focusing on the potential role of metabolic dysfunction outside the nervous system. Its preclinical programmes include a treatment candidate designed to address toxic cargo carried by exosomes to motor neurons, alongside a…
Finnish pharma company marketing and developing medicines
Orion Pharma (UK) Limited is the UK subsidiary of Orion Corporation, a Finnish pharmaceutical company. The UK entity manages commercial operations for Orion's prescription medicines portfolio across therapy areas including neurology, respiratory disease, oncology and women's health. A biologics R&D centre opened at…